{"id":1733,"date":"2006-06-01T12:02:00","date_gmt":"2006-06-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/tamoxifen-in-der-adjuvanten-hormontherapie-bei-her2-neu-positivem-mammakarzinom"},"modified":"2006-06-01T12:02:00","modified_gmt":"2006-06-01T10:02:00","slug":"tamoxifen-in-der-adjuvanten-hormontherapie-bei-her2-neu-positivem-mammakarzinom","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/tamoxifen-in-der-adjuvanten-hormontherapie-bei-her2-neu-positivem-mammakarzinom","title":{"rendered":"Tamoxifen in der adjuvanten Hormontherapie bei HER2\/neu-positivem Mammakarzinom"},"content":{"rendered":"<p>F\u00fcr die Auswahl der adjuvanten Therapie des Mammakarzinoms ist der Hormonrezeptor-Status, d.h. die Expression von \u00d6strogen- und Progesteronrezeptoren (ER\/PgR) in den Tumorzellen, von entscheidender Bedeutung. Frauen, deren Tumoren ER- und\/oder PgR-positiv sind, wird im Allgemeinen eine adjuvante Hormontherapie (pr\u00e4menopausal: Tamoxifen \u00b1 Suppression der Ovarialfunktion; postmenopausal: Tamoxifen oder Aromatasehemmer) empfohlen, die &#8211; je nach Risikogruppe &#8211; [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>F\u00fcr die Auswahl der adjuvanten Therapie des Mammakarzinoms ist der Hormonrezeptor-Status, d.h. die Expression von \u00d6strogen- und Progesteronrezeptoren (ER\/PgR) in den Tumorzellen, von entscheidender Bedeutung. Frauen, deren Tumoren ER- und\/oder PgR-positiv sind, wird im Allgemeinen eine adjuvante Hormontherapie (pr\u00e4menopausal: Tamoxifen \u00b1 Suppression der Ovarialfunktion; postmenopausal: Tamoxifen oder Aromatasehemmer) empfohlen, die &#8211; je nach Risikogruppe &#8211; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[389,146,1903,1906,1042,149,260],"class_list":["post-1733","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aromatasehemmer","tag-brustkrebs","tag-her2","tag-human-epidermal-growth-factor-receptor-2","tag-letrozol","tag-mammakarzinom","tag-tamoxifen"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1733"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1733\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}